Irritable bowel syndrome

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

Retrieved on: 
星期二, 五月 7, 2024
Patient, D.C, Safety, Food, MD, Conference, Irritable bowel syndrome, Constipation, IBS-C, DDW, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.

Key Points: 
  • WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
  • Title: Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome with Constipation in Hispanic vs Non-Hispanic Patients: A Posthoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies
    In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Discover IBSRELA: a Different Mechanism of Action to Treat Adults With IBS-C: A Case-Based Discussion,” on May 19, 2024, from 2:30-3:15 PM EDT, where Brooks Cash, MD, will lead an engaging discussion about important clinical considerations for managing IBS-C in adult patients.
  • The presentation will include interactive patient case studies, along with IBSRELA efficacy and safety data from the Phase 3 clinical trial program.

Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’

Retrieved on: 
星期五, 五月 3, 2024
Defecation, Irritable bowel syndrome, Ulcerative colitis, Inflammation, Gastroenterology, Crohn's disease, RLS, Restless legs syndrome, Research, IBD, Inflammatory bowel disease, Flatulence, Psoriasis, Health, Immune system, LDN, IBS, Medical device

Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.

Key Points: 
  • Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.
  • Low-dose naltrexone, traditionally known for its role in managing opioid and alcohol dependence, has emerged as a compelling option for addressing various gastrointestinal conditions.
  • Furthermore, Dr. Weinstock highlights the need for further research and clinical trials to fully elucidate LDN's therapeutic potential in gastroenterology.
  • For more information on Dr. Leonard Weinstock's insights into low-dose naltrexone in gastroenterology, please read his full article here .

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期五, 五月 3, 2024
Cancer, Irritable bowel syndrome, Phenotype, IL-2, Food, Research, Pembrolizumab, Colitis, Immunotherapy, PacWest Bancorp, Tumor microenvironment, Defecation, ASCO, Therapy, Immunology, Patient, Society, BPR, Poster, Clinical trial, Annual general meeting, Non-Hodgkin lymphoma, Food and Drug Administration, DSM-IV codes, Pharmaceutical industry

“Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.

Key Points: 
  • “Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.
  • Financial Results for the First Quarter of 2024:
    Cash position: As of March 31, 2024, cash and cash equivalents were $139.2 million, compared to $134.3 million as of December 31, 2023.
  • General and administrative expenses: General and administrative expenses were $5.0 million for each of the first quarters of 2024 and 2023.
  • Net loss: Net loss was $16.2 million for the first quarter of 2024, compared to $12.0 million for the same period in 2023.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期二, 四月 30, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, Research, VCF, Artificial intelligence, Dysbiosis, Personalized medicine, Multiomics, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

DUBAI, UAE, April 30, 2024 /PRNewswire/ -- BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and versatility, it promises to transform healthcare worldwide. The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

NeurAxis Announces New Medical Policy Coverage in North Dakota

Retrieved on: 
星期二, 四月 23, 2024
Irritable bowel syndrome, FDA, BCBS, Neuraxis, Ear, Abdominal pain, IBS, Health insurance

CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota.

Key Points: 
  • CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota.
  • The BCBS licensee is the largest provider of health care coverage in North Dakota, insuring and/or administering claims for over 310,000 people, effective May 6, 2024.
  • Neuraxis’ PENFS technology is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old.
  • “We are pleased to announce a new medical coverage policy, expanding our total covered lives for IB-Stim™ to approximately 16.5 million individuals, which speaks to the strength of the clinical data,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.

Biomerica provides update on inFoods® IBS expansion

Retrieved on: 
星期一, 四月 15, 2024
Irritable bowel syndrome, Pain, University, Mayo Clinic, American College, Hospital, Houston Methodist Hospital, ACG, Abdominal pain, API, GI, Patient, Diet, Physician, Trust, Harvard Medical School, Quality of life, IBS, Pharmaceutical industry

IRVINE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.

Key Points: 
  • - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas.
  • - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product.
  • IRVINE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.
  • Biomerica remains at the forefront of innovative GI solutions, with the inFoods IBS product exemplifying its dedication to improving patient lives.

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

Retrieved on: 
星期三, 五月 1, 2024
Biotechnology, Health, Science, Other Science, Pharmaceutical, PS, FDA, Irritable bowel syndrome, Safety, Functional constipation, Gastrointestinal disease, Diagnosis, NDA, Food, SBS, Ironwood Pharmaceuticals, Short bowel syndrome, Effect, Research, IBS-C, Ironwood, Constipation, DDW, STARS, FC, Drug development, Medication, IBS, Pharmaceutical industry

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting.
  • Apraglutide data from the STARS Phase III trial, which evaluated the safety and efficacy of once-weekly apraglutide in reducing PS dependency in adult patients with SBS-IF, will be presented at DDW 2024 as a late-breaker oral presentation.
  • Ironwood announced topline data from the STARS Phase III trial in February 2024.
  • The late-breaker presentation includes new apraglutide data from the STARS Phase III trial.

United States Gluten-Free Food Products Market Insights 2024: A $4.25 Billion Industry by 2029, Driven by Rising Incidence of Intolerance & Increasing Availability of Diversified Options - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 26, 2024
Food, Beverage, Retail, Online, Snack, Irritable bowel syndrome, Flour, Hain Celestial Group, Flowers Foods, Prevalence, Health, Kraft Heinz, Male, Coeliac disease, Life, Mondelez International, Arthritis, Incidence, Supermarket, Perception, Tic disorder, Bread, General Mills, Growth

The U.S. gluten-free food products market is expected to reach a value of 4.25 billion by 2029 from $2.62 billion in 2023, growing at a CAGR of 8.36%

Key Points: 
  • The U.S. gluten-free food products market is expected to reach a value of 4.25 billion by 2029 from $2.62 billion in 2023, growing at a CAGR of 8.36%
    The U.S. gluten-free food products market report contains exclusive data on 28 vendors.
  • The US gluten-free food products market is highly competitive, with established players and emerging brands competing for market share.
  • The rising incidence of celiac disease and gluten intolerance is a major driver in the U.S. gluten-free food products market.
  • The increasing availability of diversified gluten-free food options is a key driver in the U.S. market, contributing to its ongoing growth.

$1.25 Billion Parenteral Nutrition Bags Markets by Chamber Type, Consumer, End User - Global Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 19, 2024
Seniors, Pharmaceutical, Health, Parenting, Children, Baby, Maternity, Consumer, Fitness & Nutrition, Irritable bowel syndrome, Dicarboxylic acid, DSM-IV codes, Risk, Hospital, Route of administration, Indigestion, Parenteral nutrition, Prevalence, Rome process, Vitamin, Electrolyte, Incidence, Patient, Developed country, Carbohydrate, Malnutrition, Pharmacy, Element, Lipid, Growth, Infection, Pet industry

The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parenteral Nutrition Bags Market by Chamber Type (Single-Chamber Bags, Dual-Chamber Bags, Multi-Chambered Bags), Consumer (Adults, Children), End User (Healthcare Facilities, Pharmacies & Compounding Service Providers) - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global parenteral nutrition bags market is projected to reach $1.25 billion by 2031, at a CAGR of 6.6% from 2024 to 2031.
  • The lack of awareness regarding parenteral nutrition in developing countries is a major challenge impacting the growth of the parenteral nutrition bags market.
  • Among chamber types, in 2024, the single-chamber parenteral nutrition bags segment is expected to account for the largest share of the parenteral nutrition bags market.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期四, 四月 25, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, AB, VCF, Research, Dysbiosis, Personalized medicine, Multiomics, Intelligence, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.